Comments
Pharma major Lupin Ltd has received Establishment Inspection Report (EIR) from the US Food and Drug Administration for its Aurangabad facility.
The inspection for the facility was carried out by the USFDA between February 10 and February 14 and concluded with no observations, the company said in a regulatory filing.
“This takes us a step forward in our efforts of enhancing our compliance and quality standards across our manufacturing sites. We continue to work with the USFDA to continuously improve our quality and compliance while providing important medicines to the US market,” Nilesh Gupta, Managing Director, Lupin said.
Comments
COMMENT NOW
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.